Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > Population-Wide BRCA Testing

| More

Newsflash

4/17/18
FORCE and over 100 patient and professional health orgs reached out to Congressional leaders to oppose expansion of short-term health insurance plans. Read letter...

4/12/18
FDA finalizes guidances to accelerate development of reliable, beneficial next generation sequencing-based tests. Read press release...

4/9/2018
FORCE joined other organizations in urging Utah to clarify and protect coverage of breast reconstruction after cancer for its Medicaid recipients. Read more...

2/27/2018
FORCE, along with over 100 other organizations, is advocating for continued funding of DoD research programs. Read our letter to Congressional leaders.

2/7/2018
FORCE staff and advocates joined stakeholders for a "BRCA Community Perspectives on Data Sharing" workshop in Santa Cruz, CA.

2/6/2018
We joined nearly 40 patient and health care professional organizations in expressing opposition to proposed national right-to-try legislation. Read the letter...

 

Population-Wide BRCA Testing

Genetic Testing & Counseling

Overview

In 2014, Dr. Mary-Claire King, whose research led to the discovery of the BRCA1 gene associated with hereditary breast cancer and ovarian cancer, proposed that genetic testing for the BRCA1 and BRCA2 gene mutations become routine for all U.S. women over age 30. Among other things, King cited an Israeli study which revealed that Ashkenazi Jewish women with no family history of cancer—but who tested positive for a BRCA genetic mutation—have high rates of breast and ovarian cancer. 

Demonstration studies in the Ashkenazi Jewish population have shown that screening for the three BRCA founder mutations may be cost-effective and identifies carriers who would not have been suspected on the basis of their family cancer history. However, applying this to the broader, more diverse U.S. population may not yield the same results.

FORCE continues to consult with its scientific advisory board and other experts to evaluate these proposed changes and their implications on health care practice.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered